Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Mitoxantrone × Endocrine × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 140 Lymphoid 70 Genitourinary 25 Myeloid 18 Breast 6 Classical hematology 5 Sarcoma 4 Gynecologic 4 Tumor-Agnostic 2 Plasma cell 2 Head & Neck 1 Endocrine 1

Conditions

Thyroid Cancer, Papillary 1

Interventions

Everolimus 53 lutetium Lu 177 dotatate 41 Magnetic Resonance Spectroscopy 27 Cisplatin 25 pembrolizumab 24 Temozolomide 22 Octreotide 20 Nivolumab 20 lanreotide 19 gallium Ga 68 dotatate 19 Specimen Handling 17 cabozantinib 16 Etoposide 16 Sunitinib 14 Capecitabine 14 pasireotide 13 lenvatinib 13 dabrafenib 13 Paclitaxel 13 Carboplatin 13 trametinib 12 surufatinib 11 Doxorubicin 11 Bevacizumab 11 3-Iodobenzylguanidine 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Ipilimumab 10 Injections 10 Thyrotropin Alfa 9 Sorafenib 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡